A Phase 2 interventional study of Gemcitabine and Bevacizumab in Metastatic Breast Cancer and Locally Advanced Breast Cancer, sponsored by Eli Lilly and Company. Completed at 16 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-09.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing gemcitabine in Breast Neoplasms — 2 open to participants now, 5 under way, 3 of them phase 3. Gemcitabine · Breast Neoplasms.
Among the 95 studies testing gemcitabine in Breast Neoplasms, this one is the 55th largest by enrollment of the 90 interventional ones that give a count, is one of 5 that started in 2008, is one of 65 in phase 2, and was the 60th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →2 of the 95 studies testing gemcitabine in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Margaret Gatti-Mays · Sites in United States
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 73 · Phase 3 19
First in 1997; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 68 across the 90 interventional studies. Of the 78 that completed or were terminated, 34 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
88 studies in Breast Neoplasms by Eli Lilly and Company: 7 open now, 22 under way, 8 of them phase 3. Of 61 finished, 40 (66%) have results posted.
Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 65th largest by enrollment of the 80 interventional ones that give a count, is one of 3 that started in 2008, is one of 41 in phase 2, and was the 36th registered.
Eli Lilly and Company’s Breast Neoplasms studies by the year they started, since 1998.
1 of the studies testing gemcitabine in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06026657Margaret Gatti-MaysGemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies testing gemcitabine in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 88 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
To determine how long Gemcitabine and Bevacizumab will stop the cancer from growing in patients with advanced breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gemcitabine 2500 milligrams per square meter (mg/m\^2) intravenous (IV) over 30 minutes given on Day 1 every 14 days (q 14 days) until disease progression (PD) or unacceptable toxicity. Bevacizumab 10 milligrams per kilogram (mg/kg) initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity.
Drug: Gemcitabine · Drug: Bevacizumab
Gemcitabine 2500 mg/m\^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
Also known as: Gemzar, LLY188011
Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event \[AE\], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.) Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity.
Progression Free Survival (PFS) Time
PFS was measured from date of first dose to first date of progressive disease (PD) or death from any cause. For each participant who was not known to have died or to have had PD as of the data inclusion cut-off date for a particular analysis, PFS duration was censored for that analysis at the date of the participant's last progression-free tumor assessment before that cut-off date.
Time frame: Baseline to measured PD or death from any cause. Tumor assessments were performed every 8 weeks during therapy and every 2 months during post-therapy until documented PD (up to 34 months).
Overall Tumor Response Rate (ORR)
Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: complete response (CR)=disappearance of all target lesions; partial response (PR)=30% decrease in sum of longest diameter of target lesions; progressive disease (PD)=20% increase in sum of longest diameter of target lesions; stable disease=small changes that do not meet above criteria. ORR=proportion of participants who achieved a confirmed best response of CR or PR (responders). ORR=number of participants with CR or PR /number of participants qualified for tumor response analysis (per protocol population).
Time frame: Baseline to measured PD. Tumor assessments were performed every 8 weeks (q 8 weeks) during therapy and q 2 months during post-therapy until documented PD (up to 34 months).
Number of Participants With Adverse Events (AEs); Pharmacology Toxicities
A listing of serious adverse events (SAEs) and other non-serious AEs is located in the Reported Adverse Event module.
Time frame: Baseline, every cycle (every 14 days) up to 34 months
1-Year Overall Survival (OS) Rate
OS was measured from the date of first dose to the date of death from any cause. For each participant who was not known to have died as of the data inclusion cut-off date for a particular analysis, OS duration was censored for that analysis at the date of participant's last study contact prior to that cut-off date. The 1-year survival rate (percentage of participants who were alive at 1 year) was estimated from OS data.
Time frame: Baseline to death from any cause, 1 year
| Milestone | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| Started | 52 |
| Completed | 28 |
| Not completed | 24 |
| Withdrew: Adverse event | 10 |
| Withdrew: Physician decision | 10 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 3 |
PFS was measured from date of first dose to first date of progressive disease (PD) or death from any cause. For each participant who was not known to have died or to have had PD as of the data inclusion cut-off date for a particular analysis, PFS duration was censored for that analysis at the date of the participant's last progression-free tumor assessment before that cut-off date.
| months | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| Progression Free Survival (PFS) Time | 4.80 (3.42 to 7.56) |
Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: complete response (CR)=disappearance of all target lesions; partial response (PR)=30% decrease in sum of longest diameter of target lesions; progressive disease (PD)=20% increase in sum of longest diameter of target lesions; stable disease=small changes that do not meet above criteria. ORR=proportion of participants who achieved a confirmed best response of CR or PR (responders). ORR=number of participants with CR or PR /number of participants qualified for tumor response analysis (per protocol population).
| proportion of responders | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| Overall Tumor Response Rate (ORR) | 0.214 (0.1030 to 0.3681) |
A listing of serious adverse events (SAEs) and other non-serious AEs is located in the Reported Adverse Event module.
| participants | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| SAEs | 18 |
| Other non-serious AEs | 51 |
OS was measured from the date of first dose to the date of death from any cause. For each participant who was not known to have died as of the data inclusion cut-off date for a particular analysis, OS duration was censored for that analysis at the date of participant's last study contact prior to that cut-off date. The 1-year survival rate (percentage of participants who were alive at 1 year) was estimated from OS data.
| percentage of participants | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| 1-Year Overall Survival (OS) Rate | 68.68 (54.05 to 79.50) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg | — | 18/52 (34.6%) | 51/52 (98.1%) |
| Event | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/52 |
| VomitingGastrointestinal disorders | 2/52 |
| SepsisInfections and infestations | 2/52 |
| HypovolaemiaMetabolism and nutrition disorders | 2/52 |
| Renal Failure AcuteRenal and urinary disorders | 2/52 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 2/52 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/52 |
| Haemolytic Uraemic SyndromeBlood and lymphatic system disorders | 1/52 |
| LeukopeniaBlood and lymphatic system disorders | 1/52 |
| NeutropeniaBlood and lymphatic system disorders | 1/52 |
| Event | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| NauseaGastrointestinal disorders | 32/52 |
| FatigueGeneral disorders | 32/52 |
| ConstipationGastrointestinal disorders | 21/52 |
| AnaemiaBlood and lymphatic system disorders | 16/52 |
| Decreased AppetiteMetabolism and nutrition disorders | 15/52 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 15/52 |
| NeutropeniaBlood and lymphatic system disorders | 14/52 |
| VomitingGastrointestinal disorders | 14/52 |
| ProteinuriaRenal and urinary disorders | 13/52 |
| DiarrhoeaGastrointestinal disorders | 12/52 |
| Age Continuous(years) | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| Mean | 55.2 ± 11.66 |
| Sex: Female, Male(Participants) | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| Female | 52 |
| Male | 0 |
| Race/Ethnicity, Customized(participants) | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| African descent | 11 |
| Caucasian | 41 |
| Region of Enrollment(participants) | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| United States | 52 |
| Estrogen Receptor (ER) Status(participants) | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| ER+ | 33 |
| ER- | 19 |
| Progesterone Receptor (PR) Status(participants) | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| PR+ | 30 |
| PR- | 22 |
| Human Epidermal Growth Factor Receptor 2 (HER2/neu)(participants) | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| HER2/neu+ | 0 |
| HER2/neu- | 52 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Gemcitabine 2500 mg/m^2 + Bevacizumab 10 mg/kg |
|---|---|
| 0 | 28 |
| 1 | 24 |
The record gives a start of Mar 2008, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gemcitabine · Bevacizumab